Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Novel statistical approach for evaluating flow cytometric in vitro micronucleus data.

Wojciechowski JP, Gleason CR, Roberts DJ, Custer LL.

Environ Mol Mutagen. 2016 Oct;57(8):623-629. doi: 10.1002/em.22038. Epub 2016 Aug 22.

PMID:
27545269
2.

Development and Validation of Electrochemiluminescence Assays to Measure Free and Total sSLAMF7 in Human Serum in the Absence and Presence of Elotuzumab.

Postelnek J, Neely RJ, Robbins MD, Gleason CR, Peterson JE, Piccoli SP.

AAPS J. 2016 Jul;18(4):989-99. doi: 10.1208/s12248-016-9912-3. Epub 2016 Apr 26.

PMID:
27116021
3.

Evaluation of cardiac function in unrestrained dogs and monkeys using left ventricular dP/dt.

Buchanan LV, Warner WA, Arthur SR, Gleason CR, Lewen G, Levesque PC, Gill MW.

J Pharmacol Toxicol Methods. 2016 Jul-Aug;80:51-8. doi: 10.1016/j.vascn.2016.03.006. Epub 2016 Apr 8.

PMID:
27063376
4.

Impact of menstruation on select hematology and clinical chemistry variables in cynomolgus macaques.

Perigard CJ, Parrula MC, Larkin MH, Gleason CR.

Vet Clin Pathol. 2016 Jun;45(2):232-43. doi: 10.1111/vcp.12350. Epub 2016 Apr 8.

PMID:
27061515
5.

Development and Fit-for-Purpose Validation of a Soluble Human Programmed Death-1 Protein Assay.

Ni YG, Yuan X, Newitt JA, Peterson JE, Gleason CR, Haulenbeek J, Santockyte R, Lafont V, Marsilio F, Neely RJ, DeSilva B, Piccoli SP.

AAPS J. 2015 Jul;17(4):976-87. doi: 10.1208/s12248-015-9762-4. Epub 2015 May 1.

6.

Addressing drug effects on cut point determination for an anti-drug antibody assay.

Barbosa MD, Gleason CR, Phillips KR, Berisha F, Stouffer B, Warrack BM, Chen G.

J Immunol Methods. 2012 Oct 31;384(1-2):152-6. doi: 10.1016/j.jim.2012.06.014. Epub 2012 Jun 28.

PMID:
22750627
7.

Echocardiographic reference ranges for sedated healthy cynomolgus monkeys (Macaca fascicularis).

Sleeper MM, Gaughan JM, Gleason CR, Burkett DE.

J Am Assoc Lab Anim Sci. 2008 Jan;47(1):22-5.

8.

Evaluation of immunogenicity of the T cell costimulation modulator abatacept in patients treated for rheumatoid arthritis.

Haggerty HG, Abbott MA, Reilly TP, DeVona DA, Gleason CR, Tay L, Dodge R, Aranda R.

J Rheumatol. 2007 Dec;34(12):2365-73. Epub 2007 Nov 15.

PMID:
18050376
9.

Analysis of the nonclinical telemetered ECG: impact of logging rate and RR bin width in the dog and cynomolgus monkey.

Holzgrefe HH, Cavero I, Gleason CR.

J Pharmacol Toxicol Methods. 2007 Jul-Aug;56(1):34-42. Epub 2006 Dec 20.

PMID:
17258913
10.

Novel probabilistic method for precisely correcting the QT interval for heart rate in telemetered dogs and cynomolgus monkeys.

Holzgrefe HH, Cavero I, Gleason CR, Warner WA, Buchanan LV, Gill MW, Burkett DE, Durham SK.

J Pharmacol Toxicol Methods. 2007 Mar-Apr;55(2):159-75. Epub 2006 May 27.

PMID:
16857392
11.

Effects of time of administration and posture on the pharmacokinetics of cefprozil.

Shyu WC, Gleason CR, Barbhaiya RH.

Clin Pharmacokinet. 1993 Sep;25(3):237-42.

PMID:
8222462
12.

Simultaneous use of rheoencephalography and electroencephalography for the monitoring of cerebral function.

Montgomery LD, Gleason CR.

Aviat Space Environ Med. 1992 Apr;63(4):314-21.

PMID:
1319139
13.

Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects.

Barbhaiya RH, Forgue ST, Gleason CR, Knupp CA, Pittman KA, Weidler DJ, Movahhed H, Tenney J, Martin RR.

Antimicrob Agents Chemother. 1992 Mar;36(3):552-7.

14.

Comparison of the effects of food on the pharmacokinetics of cefprozil and cefaclor.

Barbhaiya RH, Shukla UA, Gleason CR, Shyu WC, Pittman KA.

Antimicrob Agents Chemother. 1990 Jun;34(6):1210-3.

15.

Comparison of cefprozil and cefaclor pharmacokinetics and tissue penetration.

Barbhaiya RH, Shukla UA, Gleason CR, Shyu WC, Wilber RB, Pittman KA.

Antimicrob Agents Chemother. 1990 Jun;34(6):1204-9.

16.

Phase I study of multiple-dose cefprozil and comparison with cefaclor.

Barbhaiya RH, Shukla UA, Gleason CR, Shyu WC, Wilber RB, Martin RR, Pittman KA.

Antimicrob Agents Chemother. 1990 Jun;34(6):1198-203.

17.

Safety, tolerance, and pharmacokinetic evaluation of cefepime after administration of single intravenous doses.

Barbhaiya RH, Forgue ST, Gleason CR, Knupp CA, Pittman KA, Weidler DJ, Martin RR.

Antimicrob Agents Chemother. 1990 Jun;34(6):1118-22.

18.

Phase I study of single-dose BMY-28100, a new oral cephalosporin.

Barbhaiya RH, Gleason CR, Shyu WC, Wilber RB, Martin RR, Pittman KA.

Antimicrob Agents Chemother. 1990 Feb;34(2):202-5.

19.

Pharmacokinetics of the novel cephalosporin cefepime (BMY-28142) in rats and monkeys.

Forgue ST, Shyu WC, Gleason CR, Pittman KA, Barbhaiya RH.

Antimicrob Agents Chemother. 1987 May;31(5):799-804.

20.

Correlation between renal membrane binding and nephrotoxicity of aminoglycosides.

Williams PD, Bennett DB, Gleason CR, Hottendorf GH.

Antimicrob Agents Chemother. 1987 Apr;31(4):570-4.

Supplemental Content

Loading ...
Support Center